June 3, 2024Open Access

Supplementary Figure S1 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer

Key points are not available for this paper at this time.

Figure S1. 225Ac-pelgi induces the phosphorylation of DNA damage markers in LNCaP, C4-2, and 22Rv1 prostate cancer cells

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Schatz et al. (Mon,) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper